2020-10-27
In latest article with @Forbespolska we’ve been discussing about our startup, investors, development plans and breakthrough MTC-Y technology. To read more —> https://www.forbes.pl/biznes/biotts-i-nosnik-transdermalny-leki-przyjmowane-przez-skore/rg6h2n4
2020-10-01
We are the new InCredibles! Biotts as the winner of the Startup Challenge contest, organized as part of European Economic Congress/ European Tech and Start-up Days 2020, we have joined Incredibles team and take part in the InCredibles acceleration program powered by Sebastian Kulczyk. InCredibles is a prestigious, international mentoring program for the most innovative startups across […]
2020-08-09
We couldn’t miss the XII edition of the European Economic Congress in Katowice!Paweł Biernat took part in the conference, that was attended by world representatives of science, business and politics. The formula of the event provides, among others, expert discussion panels from various fields from around the world, and Startups have a chance to present innovative […]
2020-07-22
– There are several routes by which drugs can penetrate through the skin. Starting from the least used, but still having great potential: sebaceous ducts and hair follicles which form a transfollicular route, leading directly into the bloodstream. Then we have a transdermal route, where an active substance goes through individual layers of cells. There is also […]
2020-06-26
We are just witnessing an innovative form of anti-diabetic drug being developed in Wrocław. Polish researchers have received more than 11 million PLN from the “Fast Track” competition in the Smart Growth programme to study the drug penetration through the skin into the bloodstream and prepare a relevant therapy implementation. In the future, this innovative drug […]
2020-06-15
Parkiet: In the first months of 2020, the number of transactions carried out by PE and VC funds decreased. One of the few actual investments was that of Montis Capital in Biotts – a biotech company. – Biotts is an exception, rather than a rule in these circumstances, as there are virtually no major investments on the market. […]